Is the prevalence of CYP2C19 genetic variants different in Pacific people than in New Zealand Europeans?
To undertake a preliminary assessment of the prevalence of CYP2C19 ultra-rapid and poor metaboliser genetic variants in Pacific people compared with NZ Europeans. Individuals who self-identified as either Pacific people (n=14) or NZ European (n=12) were genotyped for the *2, *3 or *17 functional variants of CYP2C19. There was a significantly lower frequency (P<0.01) of the CYP2C19*17 allele in Pacific people compared with NZ Europeans. No CYP2C19*17 variant alleles were detected in Pacific people in this preliminary study. The presence of CYP2C19*17 may be low in Pacific people and may lead to altered efficiency at metabolising some common drugs such as omeprazole. Further studies to confirm this preliminary finding are warranted.